Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) recently ticked higher on strong volume. About 0.21 million contracts were traded on 15-Jan-18 compared to daily average volume of 0.08 million shares. The first sale was made at $15.2 but later the stock became weaker, and closed with a gain of 4.23%. It was last traded at $16 apiece.Eiger BioPharmaceuticals, Inc. (EIGR): Buy Candidate With 101.06% Upside Potential
Eiger BioPharmaceuticals, Inc. is maintained at an average buy rating by 6 stock analysts, and there are at least 1.45% of shares outstanding that are currently legally short sold. The shares went up by 29.55% in value last month. Year-to-date it jumped 14.7%. Analysts are turning out to be more optimistic than before, with 6 of analysts who cover Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) advice adding it to buy candidate list. Wall Street experts also assign a $32.17 price target on Eiger BioPharmaceuticals, Inc., pointing towards a 101.06% rally from current levels. The stock is trading for about 3.56% more than its 52-week high.
This company shares (EIGR) so far managed to recover 162.3% since collapsing to its 52-week low. Over a month, it has seen its stock price volatility to stay at 7.93% while shortening the period to a week, volatility was 6.26%. The share price has already crossed its 20 days moving average, floating at a distance of 18.85% and sits 31.37% higher versus its 50 days moving average. When looking at the past five sessions, the stock returned 16.79% gains and is up by 64.28% compared with its 200-day moving average of $10.72. Also, Eiger BioPharmaceuticals, Inc. (EIGR) needs to expand a 36.17% increase it experienced over the past twelve months.Exact Sciences Corporation (NASDAQ:EXAS) Consensus Call At 2
As regular trading ended, Exact Sciences Corporation (EXAS) stock brought in a -$2.44 drop to $52.62. The day started at a price of $52.24 but then traded as high as $53.5 before giving part of the gains back. As for this week, analysts appear content to stick with their neutral outlook with the consensus call at 2. Exact Sciences Corporation is given 4 buy-equivalent recommendations, 0 sells and 5 holds. The company shares sank -17.26% from their peak of $63.60 and now has a $6.27 billion market value of equity.
EXAS’s mean recommendation on Reuter’s scale improved from 1.92 thirty days ago to 2.09 now, which indicates a hold consensus from the analyst community. They see Exact Sciences Corporation (EXAS) price hitting a mean target of $59.1 a share, meaning the stock still has potential that could lift the price another 12.31% Also, the recent close suggests the stock is underpriced by 27.33% compared to the most bullish target.Exact Sciences Corporation (EXAS) Returns 0.15% This Year
The company had seen its current volume reaching at 6.36 million shares in the last trade. That compares with the recent volume average of 1.83 million. At the close of regular trading, its last week’s stock price volatility was 4.37% which for the month reaches 6.79%. Exact Sciences Corporation dipped to as low as $52 throughout the day and has returned 0.15% in this year. At one point in the past year, the shares traded as low as $16.95 but has recovered 210.44% since then.